Fig. 8

Verifying the potential of H4Mscore as an immunotherapy biomarker in external immunotherapy cohorts. A Kaplan–Meier survival analyses for the high H4Mscore and low H4Mscore groups in the IMvigor210 cohort. B The H4Mscore difference between the CR/PR and SD/PD groups. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. C The proportion of patients who responded to immunotherapy in the low or high H4Mscore groups. D Differences in H4Mscore among distinct tumor immune phenotypes in the IMvigor210 cohort. E Differences in PD-L1 expression between high and low H4Mscore groups. F Differences in tumor neoantigen burden (TNB) between high and low H4Mscore groups. G Predictive value of the H4Mscore and PD-L1 expression for immunotherapy response. H Kaplan–Meier survival analyses for the high and low H4Mscore groups in the GSE91061 cohort. I The proportion of patients that responded to immunotherapy in the low or high H4Mscore groups in the GSE91061 cohort